tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CytoMed Therapeutics Advances ANGELICA Trial to Dose Level 2

Story Highlights
CytoMed Therapeutics Advances ANGELICA Trial to Dose Level 2

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from CytoMed Therapeutics Limited ( (GDTC) ) is now available.

On July 21, 2025, CytoMed Therapeutics Limited announced the successful completion of Dose Level 1 in its first-in-human Phase I dose-escalation clinical trial, known as the ANGELICA Trial. This trial evaluates the safety and tolerability of CTM-N2D, a novel allogeneic therapy using gamma delta T cells for treating advanced solid and haematological malignancies. The company is now proceeding to Dose Level 2, marking a significant milestone in its efforts to develop affordable cancer treatments. This advancement underscores CytoMed’s commitment to addressing the limitations of existing CAR-T therapies and enhancing its position in the biopharmaceutical industry.

Spark’s Take on GDTC Stock

According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.

CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.

To see Spark’s full report on GDTC stock, click here.

More about CytoMed Therapeutics Limited

CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that was incorporated in 2018. It focuses on developing novel cell-based allogeneic immunotherapies for treating various human cancers, utilizing proprietary technologies such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell. The company was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency.

Average Trading Volume: 9,084

Technical Sentiment Signal: Strong Sell

Current Market Cap: $25.39M

See more data about GDTC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1